119 related articles for article (PubMed ID: 19215191)
1. A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome.
De Giovanni C; Nicoletti G; Palladini A; Croci S; Landuzzi L; Antognoli A; Murgo A; Astolfi A; Ferrini S; Fabbi M; Orengo AM; Amici A; Penichet ML; Aurisicchio L; Iezzi M; Musiani P; Nanni P; Lollini PL
Hum Gene Ther; 2009 May; 20(5):453-64. PubMed ID: 19215191
[TBL] [Abstract][Full Text] [Related]
2. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
[TBL] [Abstract][Full Text] [Related]
3. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
[TBL] [Abstract][Full Text] [Related]
4. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
[TBL] [Abstract][Full Text] [Related]
5. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants.
Chang SY; Lee KC; Ko SY; Ko HJ; Kang CY
Int J Cancer; 2004 Aug; 111(1):86-95. PubMed ID: 15185348
[TBL] [Abstract][Full Text] [Related]
6. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent.
Nanni P; Landuzzi L; Nicoletti G; De Giovanni C; Rossi I; Croci S; Astolfi A; Iezzi M; Di Carlo E; Musiani P; Forni G; Lollini PL
J Immunol; 2004 Aug; 173(4):2288-96. PubMed ID: 15294941
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
[TBL] [Abstract][Full Text] [Related]
8. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.
Croci S; Nanni P; Palladini A; Nicoletti G; Grosso V; Benegiamo G; Landuzzi L; Lamolinara A; Ianzano ML; Ranieri D; Dall'Ora M; Iezzi M; De Giovanni C; Lollini PL
Breast Cancer Res; 2015 May; 17(1):70. PubMed ID: 25997501
[TBL] [Abstract][Full Text] [Related]
10. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2.
Piechocki MP; Pilon SA; Wei WZ
J Immunol; 2001 Sep; 167(6):3367-74. PubMed ID: 11544327
[TBL] [Abstract][Full Text] [Related]
11. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
12. Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression.
Pannellini T; Spadaro M; Di Carlo E; Ambrosino E; Iezzi M; Amici A; Lollini PL; Forni G; Cavallo F; Musiani P
J Immunol; 2006 Jun; 176(12):7695-703. PubMed ID: 16751417
[TBL] [Abstract][Full Text] [Related]
13. Antimetastatic activity of a preventive cancer vaccine.
Nanni P; Nicoletti G; Palladini A; Croci S; Murgo A; Antognoli A; Landuzzi L; Fabbi M; Ferrini S; Musiani P; Iezzi M; De Giovanni C; Lollini PL
Cancer Res; 2007 Nov; 67(22):11037-44. PubMed ID: 18006850
[TBL] [Abstract][Full Text] [Related]
14. Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice.
Sfondrini L; Rodolfo M; Singh M; Colombo MP; Colnaghi MI; Ménard S; Balsari A
Cancer Res; 2000 Jul; 60(14):3777-81. PubMed ID: 10919650
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
16. Induction of protective and therapeutic antitumour immunity using a novel tumour-associated antigen-specific DNA vaccine.
Sun W; Qian H; Zhang X; Zhou C; Liang X; Wang D; Fu M; Ma W; Zhang S; Lin C
Immunol Cell Biol; 2006 Oct; 84(5):440-7. PubMed ID: 16942487
[TBL] [Abstract][Full Text] [Related]
17. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
Nguyen-Hoai T; Baldenhofer G; Sayed Ahmed MS; Pham-Duc M; Vu MD; Lipp M; Dörken B; Pezzutto A; Westermann J
Cancer Gene Ther; 2012 Jan; 19(1):69-76. PubMed ID: 21997231
[TBL] [Abstract][Full Text] [Related]
18. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
Czerniecki BJ; Koski GK; Koldovsky U; Xu S; Cohen PA; Mick R; Nisenbaum H; Pasha T; Xu M; Fox KR; Weinstein S; Orel SG; Vonderheide R; Coukos G; DeMichele A; Araujo L; Spitz FR; Rosen M; Levine BL; June C; Zhang PJ
Cancer Res; 2007 Feb; 67(4):1842-52. PubMed ID: 17293384
[TBL] [Abstract][Full Text] [Related]
19. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins.
Quaglino E; Mastini C; Amici A; Marchini C; Iezzi M; Lanzardo S; De Giovanni C; Montani M; Lollini PL; Masucci G; Forni G; Cavallo F
Cancer Res; 2010 Apr; 70(7):2604-12. PubMed ID: 20332241
[TBL] [Abstract][Full Text] [Related]
20. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma.
Smorlesi A; Papalini F; Orlando F; Donnini A; Re F; Provinciali M
Gene Ther; 2005 Sep; 12(17):1324-32. PubMed ID: 15944732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]